Literature DB >> 18832042

Improvement of microcirculation after percutaneous transluminal angioplasty in the lower limb with prostaglandin E1.

Peter Heider1, Moritz Wildgruber, Oliver Wolf, Tibor Schuster, Werner Lutzenberger, Hermann Berger, Hans-Henning Eckstein.   

Abstract

OBJECTIVE: The aim of the study was to investigate prospectively the microcirculation after angioplasty and its improvement with additional Prostaglandin E1 (PGE1) therapy assessed by transcutaneous pressure of oxygen. PATIENTS AND METHODS: 45 patients with intermittent claudication eligible for angioplasty were enrolled in a prospective randomised controlled clinical trial. Patients received either intra-arterial bolus of 40 microg PGE1 in addition to angioplasty or a 40 microg PGE1 intravenous infusion. Control group received no trial medication. Additional 15 patients undergoing intra-arterial angiography were also investigated. tcpO(2) values were recorded distal to the PTA region before, during the intervention, 24h, 2 and 4 weeks after intervention. Clinical endpoint was the change of tcpO(2) values 4 weeks after intervention.
RESULTS: During the 4 week follow-up tcpO(2) values decreased in patients treated with angioplasty. At the same time tcpO(2) increased significantly in those patients additionally treated with intra-arterial PGE1 bolus injection as well as with intravenous PGE1 infusion.
CONCLUSIONS: Impaired microcirculation after angioplasty can be improved with additional intravenous as well as intra-arterial PGE1 administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832042     DOI: 10.1016/j.prostaglandins.2008.09.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  1 in total

Review 1.  Endovascular revascularisation versus conservative management for intermittent claudication.

Authors:  Farzin Fakhry; Hugo Jp Fokkenrood; Sandra Spronk; Joep Aw Teijink; Ellen V Rouwet; M G Myriam Hunink
Journal:  Cochrane Database Syst Rev       Date:  2018-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.